GeneDx Holdings Corp. Class A (WGS)
NASDAQ: WGS · Services-Health Services · Stamford, CT
Our rating: Positive
First call: Positive, moderate conviction, at $104.95, moderate conviction, September 17, 2026.
Breaks if: The Positive call fails if full-year revenue growth drops below 20% in the next reported annual period (from 40% today), signaling that the volume acceleration has peaked; or if free cash flow turns negative for two consecutive reported quarters, indicating the cash-generation thesis was premature. A 35% drawdown from the current price over the next twelve months, absent a broad market dislocation, would likely be pricing in the same deterioration before the financials confirm it.
Key figures
| Market value | $1.4B |
|---|---|
| Revenue, last 12 months | $461M |
| Net income, last 12 months | −$111M |
| Free cash flow, last 12 months | −$102M |
| Price to earnings | n/a |
| Free cash flow yield | −7.5% |
| Dividend yield | 0.0% |
| Operating margin | −21.6% |
| Return on equity | −41.4% |
| Beta to the S&P 500 | 1.68 |
| Volatility, annualized | 96.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $123M | 5.4% | $-0.41 | n/a |
| June 30, 2026 | $114M | 11.4% | $-0.60 | −$39M |
| March 31, 2026 | $102M | 17.4% | $-2.16 | −$39M |
| December 31, 2025 | $121M | 26.5% | $-0.61 | −$7M |
| September 30, 2025 | $117M | 51.9% | $-0.27 | $10M |
| June 30, 2025 | $103M | 45.6% | $0.36 | $8M |
| March 31, 2025 | $87M | 39.6% | $-0.23 | $4M |
| December 31, 2024 | $96M | 66.6% | $0.23 | −$6M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.14B: Claude 42%, Gemini 30%, Mistral 30%
- Diluted earnings per share are above zero: Claude 18%, Gemini 10%, Mistral 25%
- Free cash flow for the quarter is above zero: Claude 38%, Gemini 20%, Mistral 40%
14 ledger entries and 39 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.